Literature DB >> 9250845

The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance.

H Seppälä1, T Klaukka, J Vuopio-Varkila, A Muotiala, H Helenius, K Lager, P Huovinen.   

Abstract

BACKGROUND: In the early 1990s there was an increase in erythromycin resistance among group A streptococci in Finland. In response, policies regarding outpatient antibiotic therapy were changed, and nationwide recommendations were issued that called for reductions in the use of macrolide antibiotics for respiratory and skin infections in outpatients. We studied the effect of this policy on the pattern of erythromycin resistance throughout Finland.
METHODS: From 1991 through 1996, a total of 39,247 group A streptococcal isolates from throat swabs (82 percent of the isolates) and pus samples (18 percent) and 290 isolates from blood cultures were studied in regional microbiology laboratories. The susceptibility of the isolates to erythromycin was tested by the disk-diffusion or the screening-plate method.
RESULTS: Consumption of macrolide antibiotics decreased from 2.40 defined daily doses per 1000 inhabitants per day in 1991 to 1.38 in 1992 (P=0.007) and remained near the lower level during the study period. The change in consumption was followed by a steady decrease in the frequency of erythromycin resistance among group A streptococcal isolates from throat swabs and pus samples, from 16.5 percent in 1992 to 8.6 percent in 1996 (odds ratio for 1996 as compared with 1992, 0.5; 95 percent confidence interval, 0.4 to 0.5).
CONCLUSIONS: In Finland, after nationwide reductions in the use of macrolide antibiotics for outpatient therapy, there was a significant decline in the frequency of erythromycin resistance among group A streptococci isolated from throat swabs and pus samples.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250845     DOI: 10.1056/NEJM199708143370701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  247 in total

1.  Influence of prescription patterns in general practice on anti-microbial resistance in Norway.

Authors:  M Lindbaek; D Berild; J Straand; P Hjortdahl
Journal:  Br J Gen Pract       Date:  1999-06       Impact factor: 5.386

2.  Wagging the dog: antibiotic use and the emergence of resistance.

Authors:  E Lautenbach; N O Fishman
Journal:  J Gen Intern Med       Date:  1999-10       Impact factor: 5.128

3.  Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area.

Authors:  K C Chern; S K Shrestha; V Cevallos; H L Dhami; P Tiwari; L Chern; J P Whitcher; T M Lietman
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

4.  Unusual occurrence of M type 77, antibiotic-resistant group A streptococci in southern Sweden.

Authors:  A Jasir; A Tanna; A Efstratiou; C Schalén
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Antibiotic resistance: a current perspective.

Authors:  K F Barker
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

7.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  Pilot study for appropriate anti-infective community therapy. Effect of a guideline-based strategy to optimize use of antibiotics.

Authors:  J Stewart; J Pilla; L Dunn
Journal:  Can Fam Physician       Date:  2000-04       Impact factor: 3.275

9.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions.

Authors:  M Lipsitch; C T Bergstrom; B R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

10.  Forty-seven minutes a year for the patient.

Authors:  D P Gray
Journal:  Br J Gen Pract       Date:  1998-12       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.